Credit Agricole’s Mersana Therapeutics MRSN Stock Holding History

Credit Agricole’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	-$70K	–	1450
2017 Q2	$70K	Buy	+200	New	+$69.2K	﹤0.01%	1370

Other funds holding MRSN

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Credit Agricole's MRSN Position: Q3 2017 in Review

Credit Agricole sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 200 shares — an estimated $70K sold.

Credit Agricole first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $70K in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

Credit Agricole reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
Credit Agricole sold 200 Mersana Therapeutics shares in Q3 2017, an estimated $70K.
Credit Agricole first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
Credit Agricole's Mersana Therapeutics position peaked at $70K in Q2 2017.
42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on Credit Agricole's 13F filing for Q3 2017, filed 14 Nov 2017.